title: Hyperthermic isolated regional perfusion with cisplatin in the local treatment of spontaneous canine osteosarcoma: assessment of short-term effects.
abstract: To increase the effect of cisplatin on locoregional osteosarcoma, the short-term effect of hyperthermic isolated regional perfusion (HIRP) with cisplatin (30 mg/L extremity volume) was studied in 28 dogs with spontaneous osteogenic sarcoma, using clinical, radiological, and histological parameters. Thirty days postoperatively, mortality was 14.3%. Total platinum levels at the start of perfusion were 28.2 +/- 14.3 mg/L. A significant improvement (P < 0.001) in clinical score was observed in the overall group at 6 and 12 weeks after perfusion. The radiological parameter showed a stationary X-ray 2 weeks after perfusion and an improved X-ray 6 weeks after perfusion. Overall histological scores showed a moderate effect according to the Huvos classification. No additional therapeutic effect, according to the three parameters, could be demonstrated by increasing the perfusate temperature by 1 degrees C. HIRP with cisplatin is feasible in the local treatment of spontaneous osteosarcoma in dogs with acceptable locoregional toxicity. However, the histological results were modest, with none of the dogs showing a complete response 6 weeks after perfusion. Therefore, the search for the ideal perfusion agent with substantial contribution to the limb-sparing treatment in human osteosarcoma continues.
authors.affiliation: Department of Surgical Oncology, University Hospital Groningen, The Netherlands.
authors.forename: R J
authors.initials: RJ
authors.lastname: Van Ginkel
authors.forename: H J
authors.initials: HJ
authors.lastname: Hoekstra
authors.forename: F J
authors.initials: FJ
authors.lastname: Meutstege
authors.forename: J W
authors.initials: JW
authors.lastname: Oosterhuis
authors.forename: D R
authors.initials: DR
authors.lastname: Uges
authors.forename: H
authors.initials: H
authors.lastname: Schraffordt Koops
mesh_terms: D000818:Animals; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000379:methods; D002945:Cisplatin / Q000008:administration & dosage*; D004285:Dogs; D004334:Drug Administration Schedule; D006979:Hyperthermia, Induced; D012516:Osteosarcoma / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery
chemical_list: D002945:Cisplatin